We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Scales AI-Driven Personalized Health and Wellness
Read MoreHide Full Article
Key Takeaways
Hims & Hers is expanding personalized care through AI, acquisitions and
global market entry plans.
HIMS launched testosterone and menopause treatments to grow its hormonal and weight health offerings.
A new CTO and $870 million convertible note aim to accelerate HIMS's AI-powered diagnostics and treatments.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates at the intersection of consumer health, wellness and digital healthcare, blending telemedicine, personalized treatments and direct-to-consumer wellness products into a unified model. Its platform provides access to licensed healthcare professionals and personalized care plans for chronic and lifestyle conditions such as sexual health, hair loss, dermatology, mental health and weight management. This model integrates telehealth consultations, pharmacy fulfillment and recurring subscriptions — creating a recurring revenue stream while enabling precision-based, individualized care.
The company’s business model overlaps in consumer health and wellness stems from its emphasis on accessibility and personalization. Hims & Hers’ growth strategy expands beyond digital prescriptions into holistic care, supported by its acquisition of Trybe Labs for lab testing and MedisourceRx for compounding capabilities. This vertical integration enhances its precision health infrastructure. The recent appointment of AI expert Mo Elshenawy as chief technology officer (CTO) and an $870 million convertible note offering underscore its ambition to scale AI-driven diagnostics and treatments globally.
Recent category launches further broaden its consumer health portfolio. The introduction of a men’s oral testosterone line and women’s menopause and perimenopause specialty marks major entries into hormonal health, complementing the company’s expanding weight loss offerings. Coupled with its ZAVA acquisition in Europe and planned 2026 expansion to Canada, Hims & Hers is evolving into a global, technology-enabled consumer wellness provider that combines medical-grade treatment access with personalized lifestyle care.
GDRX & MED’s Consumer Health and Wellness Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) operates at the intersection of healthcare, technology and consumer wellness, connecting patients, pharmacies and drug manufacturers through its digital savings platform. In October, GDRX introduced GoodRx for Hair Loss, a men’s subscription offering virtual consultations and affordable treatments, and RxSmartSaver, a pharmacy-counter program expanding savings on brand drugs. Its collaboration with Amgen on Repatha further emphasizes GoodRx’s role in expanding affordable access and strengthening its position in the consumer health and wellness ecosystem.
Medifast, Inc. (MED - Free Report) is shifting from weight loss to metabolic health, introducing Metabolic Synchronization, which resets metabolism to reduce visceral fat and preserve lean mass. Supported by research on its Optimal Weight 5 & 1 Plan, showing 98% lean mass preservation, Medifast leverages clinical science, personalized coaching and behavioral support to enhance metabolic outcomes. Medifast’s evidence-based, coach-guided approach aligns it with the broader consumer health and wellness movement focused on longevity and vitality.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 82.2% year to date, outperforming the industry’s growth of 24.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.7X is lower than the industry’s average of 5.6X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 118.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Scales AI-Driven Personalized Health and Wellness
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , operates at the intersection of consumer health, wellness and digital healthcare, blending telemedicine, personalized treatments and direct-to-consumer wellness products into a unified model. Its platform provides access to licensed healthcare professionals and personalized care plans for chronic and lifestyle conditions such as sexual health, hair loss, dermatology, mental health and weight management. This model integrates telehealth consultations, pharmacy fulfillment and recurring subscriptions — creating a recurring revenue stream while enabling precision-based, individualized care.
The company’s business model overlaps in consumer health and wellness stems from its emphasis on accessibility and personalization. Hims & Hers’ growth strategy expands beyond digital prescriptions into holistic care, supported by its acquisition of Trybe Labs for lab testing and MedisourceRx for compounding capabilities. This vertical integration enhances its precision health infrastructure. The recent appointment of AI expert Mo Elshenawy as chief technology officer (CTO) and an $870 million convertible note offering underscore its ambition to scale AI-driven diagnostics and treatments globally.
Recent category launches further broaden its consumer health portfolio. The introduction of a men’s oral testosterone line and women’s menopause and perimenopause specialty marks major entries into hormonal health, complementing the company’s expanding weight loss offerings. Coupled with its ZAVA acquisition in Europe and planned 2026 expansion to Canada, Hims & Hers is evolving into a global, technology-enabled consumer wellness provider that combines medical-grade treatment access with personalized lifestyle care.
GDRX & MED’s Consumer Health and Wellness Platforms
GoodRx Holdings, Inc. (GDRX - Free Report) operates at the intersection of healthcare, technology and consumer wellness, connecting patients, pharmacies and drug manufacturers through its digital savings platform. In October, GDRX introduced GoodRx for Hair Loss, a men’s subscription offering virtual consultations and affordable treatments, and RxSmartSaver, a pharmacy-counter program expanding savings on brand drugs. Its collaboration with Amgen on Repatha further emphasizes GoodRx’s role in expanding affordable access and strengthening its position in the consumer health and wellness ecosystem.
Medifast, Inc. (MED - Free Report) is shifting from weight loss to metabolic health, introducing Metabolic Synchronization, which resets metabolism to reduce visceral fat and preserve lean mass. Supported by research on its Optimal Weight 5 & 1 Plan, showing 98% lean mass preservation, Medifast leverages clinical science, personalized coaching and behavioral support to enhance metabolic outcomes. Medifast’s evidence-based, coach-guided approach aligns it with the broader consumer health and wellness movement focused on longevity and vitality.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 82.2% year to date, outperforming the industry’s growth of 24.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.7X is lower than the industry’s average of 5.6X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 118.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.